John David Finley Sells 146,798 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) CEO John David Finley sold 146,798 shares of Palisade Bio stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the completion of the transaction, the chief executive officer owned 217,555 shares of the company’s stock, valued at $450,338.85. This trade represents a 40.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Palisade Bio Trading Down 1.4%

NASDAQ PALI traded down $0.03 on Wednesday, hitting $2.05. 3,270,900 shares of the stock traded hands, compared to its average volume of 4,120,142. The stock has a 50-day moving average of $1.91 and a 200 day moving average of $1.92. Palisade Bio, Inc. has a twelve month low of $0.53 and a twelve month high of $2.86. The company has a market capitalization of $355.84 million, a P/E ratio of -2.03 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, equities research analysts expect that Palisade Bio, Inc. will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Palisade Bio

Several large investors have recently added to or reduced their stakes in PALI. Cetera Investment Advisers bought a new stake in Palisade Bio in the fourth quarter valued at $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Palisade Bio during the fourth quarter valued at $26,000. Virtu Financial LLC bought a new position in shares of Palisade Bio during the fourth quarter worth about $28,000. Atom Investors LP bought a new position in shares of Palisade Bio during the fourth quarter worth about $33,000. Finally, Barclays PLC acquired a new stake in shares of Palisade Bio in the 4th quarter worth about $35,000. 11.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on PALI shares. Weiss Ratings upgraded shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Oppenheimer set a $7.00 price target on shares of Palisade Bio in a research report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th. Wolfe Research assumed coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective for the company. Finally, LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Palisade Bio currently has an average rating of “Buy” and a consensus target price of $8.83.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.